Forecasted · Cooperative Agreement
Center for Research on Complex Generics (U18) Clinical Trials Optional
Food and Drug Administration, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Center for Research on Complex Generics (U18) Clinical Trials Optional
- Issuing agency
- Food and Drug Administration (Department of Health and Human Services)
- Opportunity number
- FOR-FD-25-004
- Funding type
- Cooperative Agreement
- Funding purpose
- Food and Nutrition, Agriculture, Consumer Protection
- Status
- Forecasted
- Application deadline
- Forecasted · no application dates yet
- Published award range
- Up to $1,500,000
- Expected number of awards
- 1
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted. Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.103
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/356044 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 356044 · Funding opportunity number FOR-FD-25-004
- Posted
- August 14, 2024 · Source last updated August 14, 2024
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 83% of key fields published by the sourceNot published: eligibility criteria text, application dates.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Description (from the official listing)
The Food and Drug Administration (FDA) seeks to fund a Center for Research on Complex Generics under the terms and conditions of a cooperative agreement. The Center for Research on Complex Generics will support the FDA's efforts to enhance collaborations with the generic drug industry relating to generic drug research, to further the FDA's mission of increasing patient access to high quality, safe, and effective generic drugs.The goals of a Center for Research on Complex Generics include: 1) Facilitating engagement with generic industry representatives to help identify scientific challenges for generic product development or assessment, and helping to inform FDA about priority areas for research to address these challenges by supporting engagement and coordination between the FDA and key generic industry industry associations, companies, and representatives.2) Providing a forum for experts from FDA, academia, the generic drug industry, and elsewhere to collaborate on research related to generic products.3) Coordinating and conducting research projects pertaining to generic products, particularly complex generics.4) Hosting scientific workshops, providing training, and supporting other educational activities pertaining to generic drug research.5) Providing free and open public access to generic drug research outcomes such as scientific articles, posters, presentations, and other resources that help the generic drug industry to leverage scientific insights from FDA funded generic drug research.The Center for Research on Complex Generics is expected to complement FDA's…
Read the full description
The Food and Drug Administration (FDA) seeks to fund a Center for Research on Complex Generics under the terms and conditions of a cooperative agreement. The Center for Research on Complex Generics will support the FDA's efforts to enhance collaborations with the generic drug industry relating to generic drug research, to further the FDA's mission of increasing patient access to high quality, safe, and effective generic drugs.The goals of a Center for Research on Complex Generics include: 1) Facilitating engagement with generic industry representatives to help identify scientific challenges for generic product development or assessment, and helping to inform FDA about priority areas for research to address these challenges by supporting engagement and coordination between the FDA and key generic industry industry associations, companies, and representatives.2) Providing a forum for experts from FDA, academia, the generic drug industry, and elsewhere to collaborate on research related to generic products.3) Coordinating and conducting research projects pertaining to generic products, particularly complex generics.4) Hosting scientific workshops, providing training, and supporting other educational activities pertaining to generic drug research.5) Providing free and open public access to generic drug research outcomes such as scientific articles, posters, presentations, and other resources that help the generic drug industry to leverage scientific insights from FDA funded generic drug research.The Center for Research on Complex Generics is expected to complement FDA's existing regulatory science programs through its specific focus as a hub for coordination and engagement between FDA and the public, including academic experts, generic industry representatives, and other stakeholders.
Agency contact
Terrin Brown Grantor
terrin.brown@fda.hhs.gov